Recent Company News

• 04:04 PM ET Nov 10, 2025
  

  Mereo BioPharma Group reports Q3 EPS ($0.01) vs FactSet ($0.01) [7 est, ($0.02)-0.04] ($1.77, 0.00)

• 08:34 AM ET Aug 19, 2025
  

  āshibio announces license agreement with Mereo BioPharma for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 ($1.68, 0.00)

• 10:28 AM ET Aug 12, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (165 total)

• 07:38 AM ET Aug 12, 2025
  

  Mereo BioPharma Group reports Q2 EPS ($0.02) vs FactSet ($0.01) [6 est, ($0.02)-(0.01)] ($1.52, 0.00)

• 10:09 AM ET Aug 08, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (168 total)

• 04:44 PM ET Jul 10, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:18 AM ET Jul 10, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:58 AM ET Jul 10, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:30 AM ET Jul 10, 2025
  

  Ultragenyx Pharmaceutical lower on IA2 miss in ORBIT study ($41.44, 0.00)

• 08:18 AM ET Jul 10, 2025
  

  StreetAccount Summary - US Pre-market trading